Table 1.
Summary of Ras Alterations in the Discovery and Extension Sets
| Sample Source | |||
|---|---|---|---|
| Mutation Type | Cell Line | Tumor | Total |
| WT | 6 | 6 | |
| Kras amplification | 2 | 2 | |
| Kras G12 | 2 | 12 | 13 |
| G12C | 3 | 3 | |
| G12D | 9 | 9 | |
| G12V | 2 | 1 | |
| Kras G13 | 1 | 1 | |
| G13A | 1 | 1 | |
| Kras Q61 | 2 | 5 | 6 |
| Q61H | 2 | 1 | 2 |
| Q61L | 1 | 1 | |
| Q61R | 3 | 3 | |
| Nras A59 | 1 | 1 | |
| A59D | 1 | 1 | |
| Number of mutated samples (tumors) | 4 (2)a | 21 | 25 (23) |
| Number of total samples (tumors) | 4 (2)a | 27 | 31 (29) |
a
Four cell lines were derived from 2 additional independent tumors (2 each). In total, 29 independent tumors were evaluated; 23 (79%) had detectable Ras pathway mutations.